No data to show
XNAS
ADTX
Market cap2mUSD
Jul 14, Last price
1.19USD
1D
-0.83%
1Q
-50.62%
IPO
-99.99%
Name
Aditxt Inc
Chart & Performance
P/E
—
P/S
21.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
173.83%
Rev. gr., 5y
%
Revenues
134k
-79.23%
Net income
-34m
L+6.38%
CFO
-16.76b
L+90,131.42%
Earnings
Aug 18, 2025
Profile
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 134 -79.23% | 645 -30.90% | 934 788.96% | |||||
Cost of revenue | 27,370,836 | 26,708 | 25,870 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (27,370,702) | (26,062) | (24,936) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 5,333,439 | 544 | ||||||
Tax Rate | ||||||||
NOPAT | (32,704,141) | (26,062) | (25,480) | |||||
Net income | (34,446) 6.38% | (32,381) 14.85% | (28,194) -41.64% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 18,314 | 11,056 | 17,213 | |||||
BB yield | -73,228.75% | -551.52% | -803.81% | |||||
| Debt | ||||||||
Debt current | 6,336,895 | 17,176 | 1,497 | |||||
Long-term debt | 437,910 | 3,083 | 4,857 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 14,081 | 1,600 | ||||||
Net debt | 5,914,497 | (2,115) | 3,585 | |||||
| Cash flow | ||||||||
Cash from operating activities | (16,762,121) | (18,577) | (22,392) | |||||
CAPEX | (14) | (367) | ||||||
Cash from investing activities | (5,000,000) | (14) | (242) | |||||
Cash from financing activities | 22,498,050 | 15,920 | 17,531 | |||||
FCF | (20,405,012) | (22,881) | (24,595) | |||||
| Balance | ||||||||
Cash | 833,031 | 97 | 2,769 | |||||
Long term investments | 27,277 | 22,277 | ||||||
Excess cash | 860,302 | 22,342 | 2,722 | |||||
Stockholders' equity | (168,669,376) | (127,749) | (95,036) | |||||
Invested Capital | 183,743,538 | 163,614 | 103,624 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 132 | 302 | 46 | |||||
Price | 0.19 -97.14% | 6.63 -85.64% | 46.18 -95.69% | |||||
Market cap | 25 -98.75% | 2,005 -6.39% | 2,141 | |||||
EV | 5,339,715 | (120) | 5,727 | |||||
EBITDA | (26,753,451) | (25,520) | (24,400) | |||||
EV/EBITDA | 0.00 | |||||||
Interest | 7,364 | 6,390 | 2,286 | |||||
Interest/NOPBT | ||||||||